Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells $86,839.39 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Donald Notman sold 11,119 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total value of $86,839.39. Following the transaction, the insider now owns 193,444 shares in the company, valued at approximately $1,510,797.64. This trade represents a 5.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Donald Notman also recently made the following trade(s):

• On Friday, January 31st, Donald Notman sold 6,301 shares of Ocular Therapeutix stock. The stock was sold at an average price of $7.84, for a total value of $49,399.84.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL traded down $0.07 during mid-day trading on Friday, hitting $7.57. 770,143 shares of the stock traded hands, compared to its average volume of 906,225. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix, Inc. has a twelve month low of $4.06 and a twelve month high of $11.77. The company has a market cap of $1.19 billion, a PE ratio of -5.73 and a beta of 1.22. The firm has a 50 day simple moving average of $8.48 and a two-hundred day simple moving average of $9.00.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Scotiabank assumed coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $22.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.71.

Institutional Investors Weigh In On Ocular Therapeutix

Several hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Ocular Therapeutix by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 1,015 shares during the period. Essex Investment Management Co. LLC lifted its holdings in Ocular Therapeutix by 0.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 443,677 shares of the biopharmaceutical company's stock worth $3,860,000 after buying an additional 1,168 shares during the period. HighVista Strategies LLC lifted its holdings in Ocular Therapeutix by 5.1% during the 3rd quarter. HighVista Strategies LLC now owns 65,027 shares of the biopharmaceutical company's stock worth $566,000 after buying an additional 3,168 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Ocular Therapeutix by 11.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company's stock worth $285,000 after buying an additional 3,347 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Ocular Therapeutix by 2.7% during the 4th quarter. Rhumbline Advisers now owns 213,601 shares of the biopharmaceutical company's stock worth $1,824,000 after buying an additional 5,682 shares during the period. Institutional investors and hedge funds own 59.21% of the company's stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.